Cart
sales@molnova.com
BDTX-189
CAS No. 2414572-47-5
BDTX-189( —— )
Catalog No. M24111 CAS No. 2414572-47-5
BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 31 | In Stock |
|
| 5MG | 50 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 25MG | 178 | In Stock |
|
| 50MG | 335 | In Stock |
|
| 100MG | 498 | In Stock |
|
| 200MG | 713 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBDTX-189
-
NoteResearch use only, not for human use.
-
Brief DescriptionBDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity.
-
DescriptionBDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBLK|EGFR|HER2|RIPK2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2414572-47-5
-
Formula Weight561.03
-
Molecular FormulaC29H29ClN6O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:41.67 mg/mL (74.27 mM; Need ultrasonic)
-
SMILESC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)OCCN5CCOCC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Elizabeth Buck, et al. BDTX-189, a Potent and Selective Inhibitor of Allosteric EGFR and HER2 Oncogenic Mutations.
molnova catalog
related products
-
BTK IN-1
BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
-
BTK inhibitor 4b
BTK inhibitor 4b is a potent, highly selective inhibitors of BTK with IC50 of 4.2 and 0.9 nM against activated and unactivated BTK, respectively.
-
Atuzabrutinib
Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.
